Showing 4041-4050 of 5623 results for "".
- Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announces-positive-post-hoc-analysis-from-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2481147/Kubota Vision announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease. The primary objective of this study was to determine if emixustat re
- Shore Capital Partners Announces Sale of EyeSouth Partnershttps://modernod.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/Shore Capital Partners, a Chicago-based private equity firm, has announced the sale of EyeSouth Partners, an eye care management services organization, to Olympus Partners. Terms of the deal were not disclosed. Shore formed EyeSouth in 2017 with the goal of creating
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r
- AAO: Latest Research From the World’s Largest Eye Disease Data Registryhttps://modernod.com/news/aao-latest-research-from-the-worlds-largest-eye-disease-data-registry/2481141/The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022, the 126th annual meeting of the American Academy of Ophthalmology. &n
- Haag-Streit to Host a Series of Educational Webinars as Part of its Biometry Focus Month in Novemberhttps://modernod.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by a distinguished faculty consisting of notable key opinion leaders, complemented by Haag-Streit biometry product specialists. Hosted on Zo
- MYZE Eye Health Focused Digital Platform Launchedhttps://modernod.com/news/myze-eye-health-focused-digital-platform-launched/2481138/MYZE is a eye care engagement platform designed to help identify, treat, and manage dry eyes. It is designed to simplify the burden of dry eye identification and management by enabling “always available” screenings followed by frictionless access to products, servi
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- Johnson & Johnson Vision Introduces Tecnis Symfony OptiBlue EDOF IOL, the Latest PC-IOL Powered by InteliLight Technologyhttps://modernod.com/news/johnson-johnson-vision-introduces-tecnis-symfony-optiblue-edof-iol-the-latest-pc-iol-powered-by-intelilight-technology/2481128/Johnson & Johnson Vision announced availability of a new presbyopia-correcting IOL (PC-IOL) powered by InteliLight technology, Tecnis Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins Tecnis Synergy IOL, a hi